Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 20;11(1):41. doi: 10.1038/s41419-020-2232-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a FOXD2-AS1 mRNA expression in primary head and neck squamous cell carcinoma (HNSC) tissues (tumor) and matched normal tissues (normal) from UALCAN webserver. b, c FOXD2-AS1 mRNA expression in primary HNSC tissues from patients with different clinical stages and tumor grades from UALCAN webserver, respectively. d–f Prognostic value of FOXD2-AS1 expression in HNSC patients by using online Kaplan–Meier Plotter analysis. d Overall survival (OS) of 259 stage IV HNSC patients according the FOXD2-AS1 status. The median value of FOXD2-AS1 expression levels in these 259 tissues was used to stratify the high and low expression levels of FOXD2-AS1. e, f OS of 499 HNSC patients according the FOXD2-AS1 status. The median value and the best cutoff value of FOXD2-AS1 expression levels in these 499 tissues was used to stratify the high and low expression levels of FOXD2-AS1, respectively. g Real-time PCR analysis of FOXD2-AS1 expression in 24 primary laryngeal squamous cancer tissues and matched adjacent normal tissues. h FOXD2-AS1 expression were significantly increased in 21 out of 24 cases of tumor comparing with paired normal tissues. i FOXD2-AS1 mRNA expression in primary HNSC tissues from patients with different clinical stages. j FOXD2-AS1 mRNA expression in primary HNSC tissues from patients with different relapse status. Transcript levels were normalized to GAPDH expression. *P < 0.05, **P < 0.01, and ***P < 0.001.